Kalaris, AlloVir announce stockholder approval of merger

Kalaris and AlloVir (ALVR) announced the results for the proposals voted upon by AlloVir stockholders at a special meeting of stockholders held on March 12. The AlloVir stockholders voted in favor of all proposals at the special meeting, including to approve the proposed merger between the companies. The closing of the merger is expected to occur as soon as practicable, subject to the satisfaction or waiver of the remaining customary closing conditions. Following the closing of the merger, the combined company is expected to be renamed Kalaris Therapeutics and trade on The Nasdaq Capital Market under the ticker (KLRS).